Dermatologic and nondermatologic uses of thalidomide

Area of Science:

• Immunology and Pharmacology
• Dermatology and Oncology

Background:

• Thalidomide, a drug with a complex history, possesses immunomodulatory, anti-inflammatory, and antiangiogenic properties.
• Its mechanism involves inhibiting tumor necrosis factor-alpha and modulating leukocyte integrin expression.

Purpose of the Study:

• To comprehensively review thalidomide's mechanism of action.
• To explore its current and potential therapeutic applications in dermatology and beyond.
• To detail its known and emerging adverse effects and guidelines for safe usage.

Main Methods:

• A systematic literature search was conducted using MEDLINE, OVID, and the Cochrane Clinical Trials Register (1966-January 2003).
• Relevant articles, including non-English literature, case reports, and clinical trials, were analyzed.
• Data from abstracts, the internet, and pharmaceutical companies were also considered.

Main Results:

• Thalidomide demonstrated efficacy in treating erythema nodosum leprosum, lupus erythematosus, aphthosis, graft-versus-host disease, prurigo nodularis, and actinic prurigo.
• Emerging evidence suggests potential roles in other dermatologic and nondermatologic disorders.
• Significant risks include teratogenicity and neurotoxicity, which can be severe and irreversible.

Conclusions:

• Thalidomide is an effective treatment for various challenging conditions.
• Despite risks like teratogenicity and neurotoxicity, careful patient selection can lead to an acceptable risk-to-benefit ratio.
• The review provides a basis for thalidomide pharmacotherapy, balancing efficacy with safety.